Literature DB >> 8648237

Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease.

J A Bilello, G L Drusano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8648237     DOI： 10.1093/infdis/173.6.1524

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  7 in total

Review 1.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery.

Authors:  Dennis A Smith; Li Di; Edward H Kerns
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

Review 2.  Amprenavir: a review of its clinical potential in patients with HIV infection.

Authors:  S Noble; K L Goa
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

3.  Correlation between in vitro and in vivo activities of GM 237354, a new sordarin derivative, against Candida albicans in an in vitro pharmacokinetic-pharmacodynamic model and influence of protein binding.

Authors:  P Aviles; C Falcoz; M J Guillén; R San Roman; F Gómez De Las Heras; D Gargallo-Viola
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

4.  TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.

Authors:  Sandra De Meyer; Hilde Azijn; Dominique Surleraux; Dirk Jochmans; Abdellah Tahri; Rudi Pauwels; Piet Wigerinck; Marie-Pierre de Béthune
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

5.  The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects.

Authors:  Marta Boffito; Patrick G Hoggard; Helen E Reynolds; Stefano Bonora; E Rhiannon Meaden; Alessandro Sinicco; Giovanni Di Perri; David J Back
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

6.  Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir.

Authors:  Dean Hickman; Sudthida Vasavanonda; George Nequist; Lynn Colletti; Warren M Kati; Richard Bertz; Ann Hsu; Dale J Kempf
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

7.  Canine orosomucoid (alpha-1 acid glycoprotein) variants and their influence on drug plasma protein binding.

Authors:  Ana P Costa; Michael H Court; Nicolas F Villarino; Neal S Burke; Katrina L Mealey
Journal:  J Vet Pharmacol Ther       Date:  2020-08-03       Impact factor: 1.786
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.